Quick‑Answer
Lurbinectedin’s side‑effects are usually checked at the start of every cycle (day 1) and then at least once a week during the first cycle, with a CBC and basic metabolic panel done again before each infusion.
If you’re on a standard 3‑week (21‑day) schedule, you’ll see labs on day 1, day 8, day 15, and day 22 (the day before the next cycle).
---
Why the schedule looks that way
| What’s monitored | Why it matters | Typical timing |
|------------------|----------------|----------------|
| Complete Blood Count (CBC) with differential | Lurbinectedin can cause myelosuppression (neutropenia, thrombocytopenia, anemia). Early detection prevents severe infections, bleeding, or anemia‑related symptoms. | Day 1 of each cycle; weekly during the first cycle; before each infusion. |
| Basic Metabolic Panel (BUN, creatinine, electrolytes) | Renal function impacts drug clearance and risk of electrolyte‑related complications. | Day 1 of each cycle; repeat as needed. |
| Liver Function Tests (AST, ALT, bilirubin, alkaline phosphatase) | Hepatotoxicity is a potential side‑effect. Elevated enzymes can signal liver injury that may necessitate dose modification. | Day 1 of each cycle; repeat if baseline values were abnormal or if symptoms arise. |
| Cardiac monitoring (ECG, troponin) | Though rare, some patients may experience arrhythmias or cardiac strain, especially if they have pre‑existing heart disease. | Baseline; then at the clinician’s discretion (often only if symptomatic). |
| Patient symptom diary / check‑in | Early signs of nausea, vomiting, diarrhea, fatigue, or infections may not be captured by labs alone. | Every visit and via patient‑reported outcomes. |
---
Typical monitoring protocol (per FDA/EMA prescribing info)
1. Baseline (pre‑treatment)
* CBC, BMP, LFTs, ECG if indicated, and a full medical history.
2. During the first cycle
* CBC, BMP, LFTs on day 1 (pre‑infusion).
* CBC again on day 8 and day 15 (some centers also do day 22).
* If neutropenia (ANC < 1 × 10⁹/L) or thrombocytopenia (platelets < 75 × 10⁹/L) occurs, hold treatment until recovery to acceptable levels, then resume at a reduced dose or with granulocyte‑stimulating factor (G‑CSF).
3. Before subsequent cycles
* CBC, BMP, LFTs on day 1 of each 21‑day cycle.
* If prior cycle had significant toxicities, labs may be repeated earlier (e.g., day 8).
4. Additional monitoring
* Patients on G‑CSF: CBC daily until ANC > 1 × 10⁹/L.
* Patients with liver enzyme elevations: repeat LFTs every 1–2 weeks until stable, then at least at each cycle start.
---
Practical take‑away for patients
| Question | What you can expect |
|----------|---------------------|
| Will I need blood tests every week? | Yes, at least weekly during the first cycle; then before each infusion (often every 3 weeks). |
| How do I know when to report a problem? | Any fever ≥ 38°C, sore throat, easy bruising, unusual bleeding, severe nausea/vomiting, or persistent fatigue should prompt an immediate call to your oncology team. |
| Do I need imaging to monitor side‑effects? | Imaging is used to assess tumor response, not toxicity; labs are the main tool for monitoring adverse effects. |
| If my labs are borderline, can the treatment be continued? | The dose‑adjustment protocol is in place: the treatment may be held, reduced, or supplemented with G‑CSF depending on the severity of cytopenias or liver injury. |
---
Bottom line
- Every 3‑week cycle: CBC, BMP, LFTs on day 1.
- First cycle: additional CBC on days 8, 15, and possibly 22.
- After cycle 1: labs before each infusion.
- Symptom monitoring: continuous, with prompt reporting of infections, bleeding, or GI distress.
This schedule balances the need to catch potentially serious toxicities early while minimizing unnecessary blood draws. If you have a specific schedule prescribed by your oncologist, follow that precisely—if it deviates from the standard, your team will explain the reason.